COFEPRIS medical device registration in Mexico: the complete registration guide

The complete guide to COFEPRIS medical device registration: Classes I–III dossiers, official government fees, 5-year validity and renewal, titular structuring, MDD-to-MDR transitions, and approval timelines.

October 1, 2026

16

min read

By

BioAccess Editorial Team

Mexico

COFEPRIS

medical device registration

Class III

MDR

market access

Latin America

**Key takeaways**

• • Class III approval achievable on a timeline that varies by study (we confirm it per protocol) with optimized preparation — timelines are experience-based; confirm the current range at the proposal stage
• • Official government fees are modest: $15,896–$29,673 MXN by class in the 2025 schedule (LFD art. 195-A) — the budget sits in the dossier, translations, and local work
• • Registro valid 5 years (LGS art. 376); renew at least 150 natural days before expiry — renewals now run 10 years under the April 2026 RIS reform
• • Recommended titular structure: bioaccess® holds the registro as titular through its own Mexican entity; your distributors act as importers of record — the license is not the channel
• • MDD-to-MDR transitions require proactive planning — legacy MDD certificates remain valid only under the EU's extended transition conditions

**Who is this for?**

This guide is for regulatory affairs directors, market access managers, and MedTech company executives planning to register medical devices with COFEPRIS (Classes I–III) — particularly those navigating the EU MDD-to-MDR transition's impact on existing Mexican registrations.

**The short answer**

COFEPRIS class III approval is achievable in as little as Varies by study; we confirm per protocol with optimized dossier preparation and pre-submission engagement — and FDA 510(k) clearance accelerates review by 2–4 months as a recognized reference approval. Timelines are experience-based; bioaccess® confirms the current range at the proposal stage. Registration fees are official federal derechos — $15,896–$29,673 MXN by class in the 2025 schedule — and the registro is valid 5 years, renewable. The recommended structure: bioaccess® holds the registro as titular through its own Mexican entity while your distributors act as importers of record — the license is not the channel, so no transfer clauses and no hostage risk. Legacy MDD certificates can remain valid only under the EU's extended transition conditions — check yours against the 2027/2028 deadlines. If your Mexico strategy also involves clinical studies, see how to obtain clinical trial insurance in Latin America.

What does COFEPRIS class III registration require?

Mexico's Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS) classifies medical devices into three classes: Class I (low risk), Class II (moderate risk), and Class III (high risk). Class III devices — including implantable devices, life-supporting devices, and novel therapeutic technologies — require the most comprehensive regulatory review.

COFEPRIS Class III registration requires a complete technical dossier including device description, manufacturing information, biocompatibility data, clinical evidence, and a reference regulatory approval (FDA clearance, CE marking, or other recognized authority).

What is the process and expected timeline?

Two qualifiers on these figures. First, published maximum response terms for each class exist in COFEPRIS's official trámite catalogue (the regulatory-improvement registry), but actual review times are practice-based — they depend on dossier quality, reviewer queries, and backlog. Second, COFEPRIS leadership publicly stated in early 2026 that the historic medical-device trámite backlog was roughly 80% cleared, with full clearance targeted for the first half of 2026, and the agency has published three equivalence agreements recognizing foreign reference-authority approvals to shorten reviews. bioaccess® confirms the current expected timeline at the proposal stage based on the device's class and dossier readiness.

What does the COFEPRIS dossier require?

Mexican law requires a registro sanitario for the production, sale, and distribution of medical devices (Reglamento de Insumos para la Salud, art. 82), and the Secretaría de Salud — acting through COFEPRIS — classifies devices for registration purposes by the risk their use implies, in three classes (RIS art. 83). The device categories themselves — equipo médico, prótesis y órtesis, agentes de diagnóstico, insumos de uso odontológico, materiales quirúrgicos y de curación, productos higiénicos — come from the Ley General de Salud, article 262.

Getting the classification right at the start matters — it determines the review path, the government fee, and the evidence burden. The detailed application rules sit in the FEUM's Suplemento para Dispositivos Médicos and the classification rules COFEPRIS has issued over time.

Administrative documents

• The official COFEPRIS registration application form, completed for the device or device family with the correct class
• Designation of the Mexican titular (holder) — a legal entity domiciled in Mexico with an aviso de funcionamiento; for imported devices, the manufacturer's carta de representación (letter of representation) authorizing the titular (RIS art. 180)
• Certificate of Free Sale or Certificate to Foreign Government from the country of origin or a reference authority, where the device is legally marketed (RIS art. 180, for imported devices)
• Manufacturer's ISO 13485 certificate or good-manufacturing-practice evidence (RIS art. 180, for imported devices)
• Proof of payment of the derechos (Ley Federal de Derechos, art. 195-A)
• Spanish labeling and instructions for use; the underlying technical documentation may be submitted in Spanish or English since the 2021 reform of RIS article 153

Technical documents

• Device description, intended use, indications and contraindications, and models/variants grouped as a device family
• Classification rationale against RIS article 83, with the LGS article 262 device category
• Materials and biocompatibility summary (ISO 10993) — Class II/III
• Manufacturing process summary; sterilization method and validation summary (ISO 11135/11137); packaging and shelf-life rationale
• Risk management summary (ISO 14971) and the essential safety-and-performance checklist
• Clinical evaluation or clinical evidence summary — expected for Class III devices
• Reference approval (FDA 510(k)/PMA/De Novo, CE certificate, or another recognized authority) — COFEPRIS treats reference approvals as the basis of its review under its equivalence agreements

**Dossier depth scales with class**

Class I filings are administrative and documentary; Class II adds technical depth; Class III receives the full technical review with clinical evidence. bioaccess® confirms the exact document list for your device's class at the proposal stage — the list above is the standard expediente, not a per-device requirement.

What does COFEPRIS registration cost?

COFEPRIS registration fees are not discretionary — they are federal derechos (fees for services) fixed by the Ley Federal de Derechos, article 195-A, and updated every year for inflation in the December fiscal package. The SHCP publishes the revised cuotas in the Diario Oficial de la Federación, and COFEPRIS republishes its "cuotas vigentes" table on gob.mx each year.

The figures above are the rounded amounts from COFEPRIS's official 2025 fee schedule (published in the DOF on December 30, 2024, effective January 1–December 31, 2025). The 2026 schedule follows the same structure with the annual inflation adjustment — bioaccess® confirms the current-year amounts at the proposal stage. Government fees are a small part of the real budget: the cost drivers are dossier preparation (including any testing or clinical evidence for Class III), translations and apostilles, the Certificate of Free Sale, the Mexican titular setup, and the regulatory filing itself. Import permits, where still required per shipment, carry separate modest fees under LFD article 195-G.

How long is the registration valid, and how does renewal work?

A COFEPRIS registro sanitario is valid for 5 years from issuance (Ley General de Salud, article 376). It is not indefinite: when it expires without renewal, the device loses its authorization to be imported and sold in Mexico, and the authority may cancel the registration. Changes to the product or manufacturer made without prior authorization can also trigger cancellation (LGS art. 376) — route them through a modificación instead of letting them accumulate.

• Renewal (prórroga) is filed by the titular at least 150 natural days before expiry (Reglamento de Insumos para la Salud, art. 190 Bis 6). File on time: a timely prórroga keeps the registration in force while COFEPRIS resolves.
• Renewals granted after the April 24, 2026 RIS reform run for 10-year terms, aligning the RIS with the reformed Ley General de Salud. Registrations renewed before that date keep the 5-year term originally granted (Segundo Transitorio).
• Device prórroga requirements were simplified by the 2021 RIS reform: the filing centers on the payment of derechos, a copy of the current registro, and the tecnovigilancia report — plus, for imported devices, the manufacturer's GMP certificate or equivalent document.
• There is no grace period once the filing deadline passes. If the prórroga is not filed in time, the device must be re-registered from scratch — a fresh fee and a new review cycle — and no import or sale is lawful in the interim.

**Calendar the renewal 18 months out**

The 150-day filing deadline arrives faster than it looks once the tecnovigilancia report, the updated GMP evidence, and (for imported devices) the current carta de representación are assembled. Put the expiry on the regulatory calendar with an 18-month lead so the prórroga is filed with margin.

How does the MDD to MDR transition affect Mexico registrations?

The European Union's transition from the Medical Devices Directive (MDD 93/42/EEC) to the Medical Devices Regulation (MDR 2017/745) has created a cascading impact on device registrations worldwide — and Mexico is no exception.

As of October 2026, the EU transition is in its extended phase. Regulation (EU) 2023/607 pushed the transition deadlines to December 31, 2027 for higher-risk legacy devices (Class III and certain implantable IIb) and December 31, 2028 for medium and lower-risk devices — provided the manufacturer meets the extension conditions: a valid legacy certificate, no significant change in design or intended purpose, an MDR-compliant quality management system, and engagement with a notified body. For Mexico, this means a legacy MDD certificate that is valid under the extension still supports the COFEPRIS dossier — but a certificate that has truly lapsed, outside the transition conditions, cannot. The practical rule: verify your CE certificate's status against the 2023/607 conditions now, and begin MDR transition planning at least 12 months before your certificate's real expiry.

Case study: what happens when MDD certificates expire?

Many devices currently registered with COFEPRIS used EU CE marking under MDD as their reference regulatory approval. When that reference certificate truly expires — outside the extended transition terms — COFEPRIS requires updated documentation reflecting the new MDR certification. Failure to proactively manage this transition creates several risks:

• Registration suspension: COFEPRIS may suspend the Mexican registration if the reference CE certificate expires without a valid MDR replacement
• Re-registration requirement: In severe cases, the registration may need to be filed from scratch under the new MDR reference — adding a timeline that varies by study (we confirm it per protocol) to the process
• Commercial disruption: Any interruption in registration status means the device cannot be legally imported or sold in Mexico during the gap period
• Inventory complications: Devices in the Mexican supply chain during a registration suspension face complex regulatory status questions

**Action required: check your MDD certificate expiry**

If your Mexican device registration references an MDD CE certificate, check the certificate expiry date immediately. Begin MDR transition planning at least a timeline that varies by study (we confirm it per protocol) before expiry to avoid registration gaps. bioaccess® provides MDR transition management services for existing Mexican registrations.

How should the titular be structured?

Every COFEPRIS registro sanitario is issued in the name of a titular — a legal entity domiciled in Mexico. A foreign manufacturer cannot hold the registration in its own name; it appoints the titular through the manufacturer's carta de representación (letter of representation) (Reglamento de Insumos para la Salud, art. 180). Whoever is named titular controls the registration in practice: import authorizations, labeling decisions, and tecnovigilance reporting all run through it.

Our recommended structure for Mexico: bioaccess® holds the registro sanitario as titular through its own Mexican entity, and prepares and prosecutes the COFEPRIS filing — dossier preparation, sworn translations, agency liaison, and tecnovigilance — while your distributors act as importers of record. Keep the registration out of the distribution agreement entirely: the holder can add multiple importers to a single registro, so the license is not the channel.

With bioaccess® as titular, the protection comes from the structure, not the contract: there is no distributor-held registro to transfer if the commercial relationship changes, and no post-approval titular variation to negotiate with an uncooperative counterparty. (In Argentina, bioaccess® likewise holds the registration and additionally acts as importer of record through its integrated Argentine operation.)

**Titular choice is a commercial decision, not just a regulatory one**

Transferring titular rights later is a formal post-approval variation requiring a new manufacturer's authorization and COFEPRIS approval — a frequent friction point when the distributor holds the registration. Whoever pays for the registration controls it: a distributor that funds the filing can hold your market access hostage for months, control import and labeling decisions in the meantime, and put the registration's legal footing at risk if it ceases operations. With bioaccess® as titular, none of that applies — the registration is independent of any single commercial relationship from day one.

How do import and technovigilance work after approval?

Once COFEPRIS registration is obtained, ongoing compliance requires integration of import logistics and technovigilance reporting:

• Import permits: most shipments require a COFEPRIS permiso sanitario previo de importación tied to the registration number (Ley Federal de Derechos, art. 195-G sets the fees). Under the 2025 simplification agreements, devices listed in COFEPRIS's agreement annex no longer need a per-shipment import permit — the importer instead files a sworn declaration at customs that the product matches the annex and meets GMP and tecnovigilancia obligations. Confirm which route your device falls under at the proposal stage
• Labeling requirements: Mexican labeling must include Spanish-language instructions, NOM compliance markings, and the titular's contact information
• Adverse incident reporting (medical devices, NOM-240-SSA1-2012 §12.3.1–12.3.3, https://www.dof.gob.mx/nota_detalle.php?codigo=5275834&fecha=30/10/2012): 2 business days for a public-health threat, 10 calendar days for death or serious deterioration, 30 calendar days for other reportable incidents
• Periodic safety reports: Annual periodic safety update reports (PSURs) are required for Class III devices
• Field safety corrective actions: Any global recall or field safety action must be reported to COFEPRIS and coordinated with the Mexican market

Mexico vs. Latin America: what is the fastest path to market access?

Frequently Asked Questions

Sources and basis of this article

This article is based on the Mexican regulatory framework as of October 2026: Ley General de Salud — articles 262 (device categories), 368 and 376 (registro sanitario; 5-year validity and renewal), 295 (import requires sanitary authorization); Reglamento de Insumos para la Salud — articles 82 (registration required for devices), 83 (Class I/II/III risk classification), 153 (filing language; 2021 reform), 179–180 (registration requirements; imported-device documents including the carta de representación), and 190 Bis 6 (prórroga filing 150 natural days before expiry), with reforms published in the DOF on May 31, 2021 and April 24, 2026 (the latter aligning renewal terms to 10-year periods; see the MGK analysis of the RIS reform); Ley Federal de Derechos, article 195-A — government fees for device trámites, with the official 2025 cuota schedule published in the DOF on December 30, 2024 (schedule mirrored by the NIH ClinRegs database); COFEPRIS "cuotas vigentes" and simplification communications (gob.mx/cofepris); Regulation (EU) 2023/607 — extended MDR transitional periods (December 31, 2027 / 2028), Official Journal of the EU; and the 2025 COFEPRIS simplification and device-listing agreements — per-shipment import-permit removal for listed devices, via GT Law's July 2025 alert. This article reflects regulatory analysis with Mike Legal AI (decision support, not a licensed attorney). Fees, timelines, and resolution-level details change by COFEPRIS notice — confirm the current requirements at the proposal stage. This article is general information, not legal advice.

BA

bioaccess® · End-to-end medical device registration and market access services across the Americas, from Canada to Argentina — including COFEPRIS (Mexico), ANVISA (Brazil), INVIMA (Colombia), and ANMAT (Argentina).

Market Access Services

Mexico Overview

Ready to start your COFEPRIS registration?

Mexico's $6B+ medical device market represents the largest opportunity in Latin America. With optimized COFEPRIS submission strategies, proactive MDD-to-MDR transition planning, and bioaccess® holding the registro as titular through its own Mexican entity — so the license is never the channel — bioaccess® helps manufacturers achieve Class III registration in as little as 9 months (experience-based — bioaccess® confirms the current range at the proposal stage).

Schedule a Strategy Call

Related resources:

• Market Access Services — /market-access
• Clinical Trials in Mexico — /clinical-trials-mexico
• DIGEMAPS medical device registration in the Dominican Republic — /blog/digemaps-medical-device-registration-dominican-republic
• Early Feasibility Device Trials — /blog/early-feasibility-device-trials-latin-america-glp-gmp-sterility-requirements
• LATAM Market Entry Strategy — /blog/us-medical-device-latam-market-entry-strategy-sequence